159 related articles for article (PubMed ID: 37532560)
1. Development of Functional Chimeric Nanoparticles by Membrane Fusion of Small Extracellular Vesicles and Drug-Encapsulated Liposomes.
Fukuta T; Nishikawa A; Hiramachi A; Yamashita S; Kogure K
Biol Pharm Bull; 2023; 46(8):1098-1104. PubMed ID: 37532560
[TBL] [Abstract][Full Text] [Related]
2. A simple approach to re-engineering small extracellular vesicles to circumvent endosome entrapment.
Geng T; Tang M; Yee Paek S; Leung E; Chamley LW; Wu Z
Int J Pharm; 2022 Oct; 626():122153. PubMed ID: 36055444
[TBL] [Abstract][Full Text] [Related]
3. Functionalisation of extracellular vesicles with cyclic-RGDyC potentially for glioblastoma targeted intracellular drug delivery.
Geng T; Leung E; Chamley LW; Wu Z
Biomater Adv; 2023 Jun; 149():213388. PubMed ID: 37003022
[TBL] [Abstract][Full Text] [Related]
4. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
5. Engineered Cancer-Derived Small Extracellular Vesicle-Liposome Hybrid Delivery System for Targeted Treatment of Breast Cancer.
Zhang W; Ngo L; Tsao SC; Liu D; Wang Y
ACS Appl Mater Interfaces; 2023 Apr; 15(13):16420-16433. PubMed ID: 36961985
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.
Lee JY; Chung J; Byun Y; Kim KH; An SH; Kwon K
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281156
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sample Concentration on Nanoparticle Tracking Analysis of Small Extracellular Vesicles and Liposomes Mimicking the Physicochemical Properties of Exosomes.
Yahata S; Hirose M; Ueno T; Nagumo H; Sakai-Kato K
Chem Pharm Bull (Tokyo); 2021; 69(11):1045-1053. PubMed ID: 34719585
[TBL] [Abstract][Full Text] [Related]
8. Constant pressure-controlled extrusion method for the preparation of Nano-sized lipid vesicles.
Morton LA; Saludes JP; Yin H
J Vis Exp; 2012 Jun; (64):. PubMed ID: 22760481
[TBL] [Abstract][Full Text] [Related]
9. Development of Enzymatic Depletion Methods for Preparation of Small Extracellular Vesicles with Long Blood-Circulation Half-Life.
Kobayashi Y; Kitamura S; Takahashi Y; Takakura Y
Pharm Res; 2023 Apr; 40(4):855-861. PubMed ID: 36195822
[TBL] [Abstract][Full Text] [Related]
10. TIM4-Affinity Methods Targeting Phosphatidylserine for Isolation or Detection of Extracellular Vesicles.
Yoshida T; Hanayama R
Methods Mol Biol; 2022; 2466():23-36. PubMed ID: 35585308
[TBL] [Abstract][Full Text] [Related]
11. An in vitro lipid-mixing assay to investigate the fusion between small extracellular vesicles and endosome.
Takeda A; Tachibana A; Nagumo H; Sakai-Kato K
Anal Biochem; 2023 May; 669():115130. PubMed ID: 36963556
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial Polydopamine-Liposome Nanoformulation as an Effective Anti-Breast Cancer Therapy.
Lu W; Liu W; Hu A; Shen J; Yi H; Cheng Z
Int J Nanomedicine; 2023; 18():861-879. PubMed ID: 36844433
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
[TBL] [Abstract][Full Text] [Related]
14. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
15. Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.
Hameed S; Bhattarai P; Liang X; Zhang N; Xu Y; Chen M; Dai Z
Theranostics; 2018; 8(19):5501-5518. PubMed ID: 30555560
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
18. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
[TBL] [Abstract][Full Text] [Related]
19. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes.
Thierry AR; Vigé D; Coughlin SS; Belli JA; Dritschilo A; Rahman A
FASEB J; 1993 Apr; 7(6):572-9. PubMed ID: 8097173
[TBL] [Abstract][Full Text] [Related]
20. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
